5,478 Shares in VanEck Biotech ETF (NASDAQ:BBH) Purchased by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. purchased a new stake in shares of VanEck Biotech ETF (NASDAQ:BBH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,478 shares of the company’s stock, valued at approximately $860,000. Tocqueville Asset Management L.P. owned 0.23% of VanEck Biotech ETF at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Farther Finance Advisors LLC bought a new position in VanEck Biotech ETF in the 4th quarter worth $32,000. HighTower Advisors LLC raised its stake in VanEck Biotech ETF by 12.0% in the fourth quarter. HighTower Advisors LLC now owns 9,903 shares of the company’s stock worth $1,554,000 after buying an additional 1,058 shares in the last quarter. Independent Advisor Alliance purchased a new stake in VanEck Biotech ETF in the fourth quarter worth about $250,000. Raymond James Financial Inc. purchased a new stake in VanEck Biotech ETF in the fourth quarter worth about $3,381,000. Finally, SBI Securities Co. Ltd. bought a new stake in VanEck Biotech ETF during the 4th quarter valued at approximately $81,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

Shares of NASDAQ:BBH opened at $162.46 on Thursday. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64. The firm has a market capitalization of $396.40 million, a P/E ratio of 33.67 and a beta of 0.85. The stock has a 50 day moving average price of $162.86 and a 200-day moving average price of $167.38.

VanEck Biotech ETF Dividend Announcement

The company also recently disclosed a dividend, which was paid on Tuesday, December 24th. Shareholders of record on Monday, December 23rd were issued a $1.2517 dividend. The ex-dividend date was Monday, December 23rd.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.